drugset / Trial / NCT06604767
Study of a Respiratory Syncytial Virus/Human Metapneumovirus/Parainfluenza Virus Type 3 Vaccine Candidate in Adults Aged 60 Years and Older
RandomizedParallel-groupTriple-blindPrevention
Summary
The purpose of this phase 1 study is to evaluate whether the vaccine is safe and can help the body to develop germ fighting agents called "antibodies" (immunogenicity) against the respiratory syncytial virus (RSV), human metapneumovirus (hMPV), and parainfluenza virus type 3 (PIV3). The study will use different doses of PIV3 only and different combinations of RSV/hMPV/PIV3 or RSV/hMPV or only RSV vaccine in adults aged 60 years and older.
Timeline
- Start
- 2024-09-17
- Primary completion
- 2026-03-24
- Completion
- 2026-03-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RSV vaccine 1 | Vaccine | — | Intramuscular |
| Subject | RSV vaccine 2 | Vaccine | — | Intramuscular |
| Subject | RSV/hMPV vaccine | Vaccine | — | Intramuscular |
| Subject | RSV/hMPV/PIV3 vaccine | Vaccine | — | Intramuscular |
| Subject | parainfluenza virus type 3 vaccine | Vaccine | — | Intramuscular |